Global Blood Therapeutics Reports Recent Business Progress And Provides Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the second quarter ended June 30, 2017.
"Regulatory authorities in the U.S. and EU are increasingly working to address the need for new treatment options for sickle cell disease or SCD. We support these efforts and remain committed to working collaboratively with the SCD community to bring a new and potentially disease-modifying therapy to patients,” said Ted W. Love, M.D., president and chief executive officer of GBT. “During the second quarter, we made significant progress toward our goal of developing GBT440 as a potential global treatment option for SCD patients of all ages.
"Regulatory authorities in the U.S. and EU are increasingly working to address the need for new treatment options for sickle cell disease or SCD. We support these efforts and remain committed to working collaboratively with the SCD community to bring a new and potentially disease-modifying therapy to patients,” said Ted W. Love, M.D., president and chief executive officer of GBT. “During the second quarter, we made significant progress toward our goal of developing GBT440 as a potential global treatment option for SCD patients of all ages.